Know Cancer

or
forgot password

Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents


N/A
N/A
N/A
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents


OBJECTIVES:

- To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3
(FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD
scid gamma (NSG) mice.

- To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase
inhibitors.

OUTLINE: Human acute myeloid leukemia cells are injected into NSG mice. Mice are then
treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood
and tissue samples are collected biweekly or weekly and analyzed for the presence of human
CD45+ and CD33+ cells by quantitative flow cytometry.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Cryopreserved human AML samples

- FLT3-ITD samples with high allelic ratios

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Ratio of human AML cells to murine cells

Safety Issue:

No

Principal Investigator

Sarah K. Tasian, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Hospital of Philadelphia

Authority:

United States: Federal Government

Study ID:

CDR0000730390

NCT ID:

NCT01576185

Start Date:

April 2012

Completion Date:

Related Keywords:

  • Leukemia
  • childhood acute myeloid leukemia/other myeloid malignancies
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location